Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03367793 · ClinicalTrials.gov registry record · NA
Spectacles for Patients With Down Syndrome
A NA study, sponsored by University of Houston.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT03367793: Completed NA study, sponsored by University of Houston.
NCT03367793 is a NA study that has completed, run by University of Houston. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03367793, a NA study, has completed, sponsored by University of Houston.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study tests the hypothesis that objectively derived spectacle prescriptions based on wavefront aberration measurements of the eyes of individuals with Down syndrome can provide an improvement in visual acuity over that obtained with spectacle prescriptions based on standard clinical prescribing techniques. The objectively derived prescriptions are derived using strategies to optimize retinal image quality as measured by image quality metrics, and thus these prescriptions will be referred to as metric-derived.
Primary Outcome
Aided LogMAR distance visual acuity obtained with either the British Standard Letters or HOTV - matching for subjects unable to name letters.
Interventions
- DEVICE Spectacles - Clinically Derived
- DEVICE Spectacles - Metric Technique #1 Derived
- DEVICE Spectacles - Metric Technique #2 Derived
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-01-26 |
| Est. Completion | 2019-12-05 |
| Phase | NA |
What the finished NCT03367793 record still lists
NCT03367793 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 3 interventions - of which Spectacles - Clinically Derived is the first listed.
NCT03367793 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03367793 about?
NCT03367793 is a clinical study titled "Spectacles for Patients With Down Syndrome". This study tests the hypothesis that objectively derived spectacle prescriptions based on wavefront aberration measurements of the eyes of individuals with Down syndrome can provide an improvement in visual acuity over that obtained with spectacle prescriptions based on standard clinical prescribing...
What is the current status of trial NCT03367793?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2018-01-26. Estimated completion is 2019-12-05.
What interventions are being tested in trial NCT03367793?
The interventions under investigation include: Spectacles - Clinically Derived (DEVICE), Spectacles - Metric Technique #1 Derived (DEVICE), Spectacles - Metric Technique #2 Derived (DEVICE).
Who is sponsoring clinical trial NCT03367793?
This trial is sponsored by University of Houston, which has 64 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03367793's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI